Abstract
Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Current Medicinal Chemistry
Title: PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Volume: 17 Issue: 36
Author(s): M. Mazzoletti and M. Broggini
Affiliation:
Keywords: PI3K, mTOR, anti-cancer drugs, drug combination, gynaecological malignancies, Ovarian cancer, malignancy, receptor tyrosine kinases (RTKs), G protein-coupled receptors, phosphorylate phosphoinositides (PIs), Pleckstrin Homology, tuberous sclerosis, signaling nodes, PI3K INHIBITORS, synergistic effects, paclitaxel, carboplatin, tumor xenografts, glucose homeostasis, phosphoinositide, API-2, macrolide Rapamycin, bevacizumab, Topotecan, pegylated doxorubicin, PI3K-like kinase (PIKK), chemotherapy, angiogenesis, hypoxia, metformin, rapalogs, regimens
Abstract: Phisiological activation of PI3K pathway is necessary for cells to regulate many different physiological processes such as transcription, protein synthesis, metabolic responses and membrane trafficking. Abnormal activation of the PI3K pathway leads to an increased activity resulting in tumor onset, maintenance, progression and invasion. Both genetic and epigenetic alterations could affect the normal pathways activation. Ovarian cancer is the leading cause of death from gynaecological malignancies in the western world. PI3K pathway has been recorded as one of the most deregulated signalling pathway in many tumors, including ovarian ones. So it could be considered an attractive target to be investigated with the various classes of chemical compounds already present or in development. In this rewiew well try to discuss the published data of the inhibitors targeting members of the PI3K/ akt/ mTOR pathway in the ovarian cancer setting from a preclinical and clinical point of view, with particular emphasis on drugs combination and strategies of administration. Relevant issues and limitations to the use of particular compounds will be also addressed.
Export Options
About this article
Cite this article as:
Mazzoletti M. and Broggini M., PI3K/AKT/mTOR Inhibitors In Ovarian Cancer, Current Medicinal Chemistry 2010; 17 (36) . https://dx.doi.org/10.2174/092986710794182999
DOI https://dx.doi.org/10.2174/092986710794182999 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Electrochemical Sensing of Cancer Biomarkers Based on
Nanomaterial - Modified Systems
Current Analytical Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Sterols and Triterpenoids with Antiviral Activity
Anti-Infective Agents in Medicinal Chemistry Telomeres, Genomic Instability, DNA Repair and Breast Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Momordicacharantia: A New Strategic Vision to Improve the Therapy of Endoplasmic Reticulum Stress
Current Pharmaceutical Design Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology Allied to Nitric Oxide Release Materials for Dermatological Applications
Current Nanoscience Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Enantiopure Drugs and Drug Intermediates by Immobilized Lipase-Catalysis
Current Bioactive Compounds MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets LncRNA, Important Player in Bone Development and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Peptide Aptamers with Biological and Therapeutic Applications
Current Medicinal Chemistry Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets miR-375 Inhibits the Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma by Targeting XPR1
Current Gene Therapy Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry